肝胆相照论坛

标题: Hepatitis C treatment gets personal: predicting drug response [打印本页]

作者: StephenW 时间: 2011-9-14 21:08 标题: Hepatitis C treatment gets personal: predicting drug response

本帖最后由风雨不动于 2012-4-14 15:46 编辑

Hepatitis C treatment gets personal: predicting drug response

Around 3% of the world’s population is infected with hepatitis C virus (HCV), which affects the liver. The current standard-of-care therapy is not effective in the majority of genotype 1 viral cases and more serious, chronic diseases of the liver can result. Recently published in Genome Medicine, David Booth and colleagues from the Universities of Sydney and Melbourne use a powerful sequencing approach to identify DNA variants that can predict failure to respond to hepatitis C therapy. Their findings could help to optimize treatment options for many hepatitis C patients.
The recommended treatment for HCV infection is a 48-week course of pegylated interferon alpha and ribavirin, which clears the infection in less than 50% of genotype 1 cases. Over the past few years, researchers have performed genome-wide association studies (GWAS) to identify genetic factors underlying the lack of viral clearance in most patients. These analyses revealed that single nucleotide changes, or polymorphisms, in the IL28B gene region can predict non-response to treatment. In their latest study, David Booth and colleagues used a high-throughput “massively parallel sequencing” approach to identify new, highly sensitive genetic predictors of drug response. DNA samples from responders or non-responders were pooled, so that many patients could be screened simultaneously and cost-effectively for common mutations. Compared with previous results, the genetic variants identified through this analysis were shown to predict failure to respond with high sensitivity and specificity.

By predicting which patients are unlikely to respond to the standard treatment, clinicians would be able to make an informed choice about which patients should be offered newly emerging therapies. These results therefore hold great promise for the clinical management of hepatitis C.

(6.合.彩)足球.篮球...各类投注开户下注

第一投注现金网:招代理年薪10万以上:yyu.cc

作者: wa3006 时间: 2011-9-15 14:02

世界人口的约3％感染丙型肝炎病毒（HCV），从而影响到肝脏。现行标准的护理治疗，大部分基因1型病毒的情况下，更严重的慢性疾病，肝脏不能有效的结果。最近发表在医学基因组，大卫展位和他的同事从大学的悉尼和墨尔本的使用功能强大的测序方法来识别DNA变异，可以预测故障应对丙型肝炎治疗。他们的发现可能有助于优化很多丙肝患者的治疗方案。-----------------可能！！

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)